Patent Document ID: 9657268
Application ID: 14525919
Patent Flag: 1

Claim One:
1. A method for treating multiple sclerosis in a human patient, comprising administering a population of neural precursors to the patient, wherein said population of neural precursors is derived by a process comprising the steps of (a) expanding a population of autologous mesenchymal stem cells from the patient in growth serum comprising autologous serum; (b) culturing the expanded population of mesenchymal stem cells in a neural progenitor basal medium (NPBM) supplemented with epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and neural cell survival factor-1 (NSF-1), and (c) collecting floating cell clusters from the NPBM-cultured cells, thereby obtaining said population of neural precursors, and wherein said population of neural precursors has increased expression of nestin, glial fibrillary acidic protein (GFAP), and neurofilament-M (NF-M), and decreased expression of alpha smooth muscle (αSM) actin, relative to the expression of nestin, GFAP, NF-M, and αSM actin in the population of mesenchymal stem cells from which the population of neural precursors is derived.